Alaska at a glance
| Adults with obesity (CDC) | 33.0% (2025) |
|---|---|
| Medicaid pays for GLP-1s for obesity | No (KFF, Jan 2026) |
| Medicare GLP-1 Bridge | $50 copay for eligible Part D members, Jul 1, 2026 – Dec 31, 2027 |
| Physician licensing | Alaska State Medical Board |
| Pharmacy licensing | Alaska Board of Pharmacy |
| Main metro areas | Anchorage |
In short, the CDC puts adult obesity in Alaska at 33.0% for 2025, tied 29th among the 47 states it reported that year. Alaska Medicaid did not pay for GLP-1s prescribed for obesity in KFF’s January 2026 survey; diabetes coverage is a separate benefit.
Insurance and public coverage in Alaska
Medicaid. Alaska Medicaid did not pay for GLP-1s prescribed for obesity in KFF’s January 2026 survey; diabetes coverage is a separate benefit.
Medicare. Medicare still cannot pay for drugs used only for weight loss under Part D, but the Medicare GLP-1 Bridge is a separate CMS program: from July 1, 2026 to December 31, 2027, eligible Part D members in Alaska pay $50 a month for Wegovy (pen or pill), Foundayo or the Zepbound KwikPen after prior authorization. The BALANCE model’s Part D arm will not start in 2027. Open enrollment runs October 15 to December 7, 2026.
Self-pay prices for Alaska residents
None of the programs we track charges Alaska a different price. These figures were read on the sellers’ own pages:
| Program | Product | Self-pay price | Read (2026) |
|---|---|---|---|
| NexLife (our #1) | Compounded semaglutide | $119/mo on a 12-month plan charged monthly; $139 month to month; no membership | Oct 14 |
| Collective | Compounded semaglutide | $59/mo plus a $199 yearly membership (about $76/mo) | Oct 14 |
| Wegovy pill (NovoCare) | Brand, FDA-approved | $149, $199 or $299 a month by dose | Oct 14 |
| Wegovy pen (NovoCare) | Brand, FDA-approved | $349 a month ($199 for the first two fills for new patients through Dec 31, 2026) | Oct 14 |
Every program with its billing basis and read date is on the compounded GLP-1 price comparison; the cheapest options are on cheapest compounded semaglutide online.
Checking the prescriber and pharmacy
A telehealth clinician who prescribes to you in Alaska needs a license Alaska recognizes. Physicians answer to the Alaska State Medical Board; you can also search any physician on DocInfo.org. The pharmacy named on your vial label should be licensed by, or hold a nonresident permit from, the Alaska Board of Pharmacy. Our pharmacy profiles summarise FDA records for common compounders, and the 503A vs 503B guide explains the two license types.
Shipments go by mail across Alaska, including the Anchorage.
Questions people in Alaska ask
Does Medicaid in Alaska pay for Wegovy for weight loss?
Alaska Medicaid did not pay for GLP-1s prescribed for obesity in KFF’s January 2026 survey; diabetes coverage is a separate benefit. Wegovy prescribed to lower heart risk is handled under different rules.
Can someone on Medicare in Alaska get Wegovy for $50 a month?
Possibly. Since July 1, 2026, the Medicare GLP-1 Bridge has let eligible Part D members anywhere in the U.S., including Alaska, fill Wegovy, Foundayo or the Zepbound KwikPen for a $50 monthly copay. It runs through December 31, 2027, uses BMI-based criteria and needs prior authorization; open enrollment runs October 15 to December 7, 2026.
What does semaglutide cost in Alaska without insurance?
Prices are national, so Alaska pays the same as other states. On October 14, 2026: compounded semaglutide $119 a month at NexLife on a 12-month plan charged monthly, or $59 plus a $199 yearly membership at Collective; brand Wegovy $149–$299 (pill) or $349 (pen) through NovoCare.
How can I check that an online prescriber is licensed in Alaska?
Look the clinician up on the Alaska State Medical Board website or on DocInfo.org. Nurse practitioners in Alaska are licensed separately, usually by the board of nursing.
Is compounded semaglutide allowed in Alaska?
Yes, within federal limits. A pharmacy licensed by, or permitted to ship into, Alaska may compound it for you on an individual prescription, but compounded semaglutide is not FDA-approved and FDA has warned sellers who market copies or salt forms. Check the pharmacy with the Alaska Board of Pharmacy.
How many adults in Alaska have obesity?
The CDC puts adult obesity in Alaska at 33.0% for 2025, tied 29th among the 47 states it reported that year. Wegovy is approved for adults with a BMI of 30 or more, or 27 or more with a weight-related condition.
Neighbouring states
Washington. See all state guides, the provider comparison or our NexLife review.
Sources
Informational only, not medical advice. Compounded semaglutide is not FDA-approved and is not the same product as Wegovy® or Ozempic® (trademarks of Novo Nordisk).